Related Experiment Video
Updated: Jul 8, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Renal protection: are all antihypertensive drugs comparable?
Rashida Blake1, Leopoldo Raij, Ivonne Hernandez Schulman
1University of Miami Miller School of Medicine, Nephrology-Hypertension Section, Veterans Affairs Medical Center, 1201 NW 16 Street , Miami, FL 33125, USA.
Abstract:
Chronic kidney disease, stage 3 or higher, affects approximately 20 million people in the United States. Aggressive management of blood pressure is critical to slow the decline in renal function. Despite adequate control, however, patients continue to progress to end-stage renal disease. A surrogate marker for renal parenchymal injury is the presence of proteinuria. Blood pressure reduction per se has been shown to decrease proteinuria. However, certain classes of antihypertensive agents, namely the inhibitors of the renin-angiotensin-aldosterone system, exert antiproteinuric and renoprotective effects that are in addition to, but independent of, blood pressure lowering. This article reviews the beneficial renoprotective effects of various classes of antihypertensive agents in chronic kidney disease.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Action of Diuretics
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Diuretics